We are pleased to announce the successful sale of Avomeen Holdings, LLC (“Avomeen”) to Element Materials Technology.

Avomeen is a leader in analytical testing and development services for key life sciences end markets, with a specific focus on pharmaceutical testing, biotechnology, and FDA-regulated products.

This sale is the result of an effective partnership between High Street Capital and the Company’s management team, which began in 2016. Mark Harvill, Avomeen CEO remarked, “High Street Capital was an outstanding partner during their five-year hold period.  We collaboratively laid out a plan for growth that re-envisioned our go-to-market strategy, service offerings, and operational capabilities. We expanded our team, built new bioanalytical capabilities, upgraded our instrumentation, and relaunched our brand.  These strategic efforts fueled our growth and have positioned us for continued success in the future.”

Tim Kurth, a High Street Capital Partner, commented, “We put our growth capital and business expertise to work at Avomeen which led to a stronger management team, differentiated services, significantly improved customer retention / loyalty, high performing sales and marketing engines and record-setting revenue / EBITDA.”

The sale of Avomeen marks the fifth exit for High Street Capital IV.

We are actively seeking new investment opportunities for High Street Capital V, in the areas of outsourced business services, niche manufacturing and value-added distribution. High Street Capital V is a $165,000,000 fund raised in 2018.  Please contact us for businesses with revenues up to $100 million and EBITDA over $3mm where the combination of our capital, experience and ideas could drive future growth.

Please follow us on LinkedIn and Twitter for the latest news.